{"id":68994,"date":"2026-03-12T15:22:39","date_gmt":"2026-03-12T15:22:39","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=68994"},"modified":"2026-05-21T07:14:11","modified_gmt":"2026-05-21T07:14:11","slug":"cjc-1295-with-dac","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/cjc-1295-with-dac\/","title":{"rendered":"CJC-1295 with DAC"},"content":{"rendered":"

<\/p>\n

\n

Quick Answer \u2014 What is CJC-1295 with DAC?<\/h3>\n

CJC-1295 with DAC<\/strong> is a synthetic analog of growth-hormone-releasing hormone (GHRH 1-29) modified with a Drug Affinity Complex (DAC)<\/strong> that binds plasma albumin covalently. The albumin binding extends plasma half-life from ~30 minutes to approximately 7\u00a0days, enabling weekly or twice-weekly research dosing. It is supplied in 2\u00a0mg and 5\u00a0mg lyophilized vials for laboratory research use only.<\/p>\n<\/div>\n

Co z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdzkumn\u00e9 lyofilizovan\u00e9 peptidy \u00b7 HPLC \u010distota \u226599% (COA na vy\u017e\u00e1d\u00e1n\u00ed) \u00b7 Diskr\u00e9tn\u00ed teplotn\u011b stabiln\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 p\u0159eprava peptid\u016f \u00b7 1,400+ ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specifikace<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
CAS \u010d\u00edslo<\/strong><\/td>\n863288-34-0<\/td>\n<\/tr>\n
item2<\/strong><\/td>\nC165<\/sub>H269<\/sub>N47<\/sub>O46<\/sub><\/td>\n<\/tr>\n
item7<\/strong><\/td>\n3647.25 Da<\/td>\n<\/tr>\n
item9<\/strong><\/td>\nD-Ala-Tyr-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-NH2<\/sub> conjugated to maleimidopropionyl-Lys (DAC linker for albumin binding)<\/td>\n<\/tr>\n
item11<\/strong><\/td>\nitem12<\/td>\n<\/tr>\n
item13<\/strong><\/td>\n\u226599% (HPLC ov\u011b\u0159eno, COA na vy\u017e\u00e1d\u00e1n\u00ed)<\/td>\n<\/tr>\n
Skladov\u00e1n\u00ed<\/strong><\/td>\nLyofilizovan\u00e9: 2\u20138 \u00b0C (lednice) pro pracovn\u00ed z\u00e1sobu; \u221220 \u00b0C pro dlouhodob\u00e9 skladov\u00e1n\u00ed neotev\u0159en\u00fdch vialek. Rekonstituovan\u00e9: 2\u20138 \u00b0C, pou\u017eijte do ~30 dn\u016f. Chra\u0148te p\u0159ed sv\u011btlem. Nefreeze\u2013thaw rekonstituovan\u00fd roztok.<\/td>\n<\/tr>\n
Rozpustnost<\/strong><\/td>\nBakteriostatick\u00e1 voda (doporu\u010deno) nebo steriln\u00ed voda pro krat\u0161\u00ed dobu pou\u017eit\u00ed<\/td>\n<\/tr>\n
Pouze pro v\u00fdzkum<\/strong><\/td>\nPouze pro laboratorn\u00ed v\u00fdzkum. Nen\u00ed ur\u010deno pro diagnostick\u00e9 nebo terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed nebo zv\u00ed\u0159at.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

What Is CJC-1295 with DAC?<\/h2>\n

CJC-1295<\/strong> is a synthetic 30-amino-acid analog of growth-hormone-releasing hormone (GHRH), specifically a modified form of the biologically-active GHRH (1-29) fragment. The “with DAC<\/strong>” suffix refers to a proprietary Drug Affinity Complex (DAC)<\/strong> \u2014 a maleimidopropionic acid residue attached to lysine-30 \u2014 which forms a covalent bond with serum albumin cysteine-34 in vivo<\/em>.<\/p>\n

That albumin tether is the key innovation. Native GHRH has a plasma half-life measured in minutes (rapid DPP-IV degradation); CJC-1295 with DAC circulates bound to albumin for approximately 7 dnech<\/strong>, enabling weekly or twice-weekly research dosing while sustaining GH\/IGF-1 elevation between injections. This is a fundamentally different pharmacokinetic profile from the “without DAC” version (sometimes called Mod GRF 1-29) which retains native GHRH’s short half-life. Developed by ConjuChem, CJC-1295 is ur\u010den pouze pro laboratorn\u00ed v\u00fdzkum<\/strong> and is not intended for human or veterinary diagnosis or therapy. For mechanism, research context, and stacking protocols, see our Ipamorelin & CJC-1295 research guide<\/a>.<\/p>\n

Mechanism of Action \u2014 Extended-Release GHRH Agonism<\/h2>\n

CJC-1295 with DAC acts through two sequential mechanisms:<\/p>\n